Clinical Trials at Xianmin Song
During the past decade, Xianmin Song conducted 5 clinical trials. In the 10-year time frame, 5 clinical trials started and 0 clinical trials were completed, i.e. on
average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 0 clinical trials were completed. i.e. 0%
of trials that started reached the finish line.
Clinical Trials Sponsors and Collaborators
Clinical Trials Conditions at Xianmin Song
According to Clinical.Site data, the most researched conditions in "Xianmin Song" are
"Acute Myeloid Leukemia" (1 trials), "Acute T Cell Leukemia" (1 trials), "Anaplastic Lymphoma" (1 trials), "Angioimmunoblastic T-cell Lymphoma" (1 trials) and "Chronic GVHD" (1 trials). Many other conditions were trialed in "Xianmin Song" in a lesser frequency.
Clinical Trials Intervention Types at Xianmin Song
Most popular intervention types in "Xianmin Song" are "Drug" (5 trials). Other intervention types were less common.
The name of intervention was led by "ATG/PTCy" (1 trials), "Azacitidine combined with interferon preemptive treatment" (1 trials), "Cytarabine" (1 trials), "Fludarabine" (1 trials) and "Prednisone" (1 trials). Other intervention names were less common.
Clinical Trials Genders at Xianmin Song
The vast majority of trials in "Xianmin Song" are
5 trials for "All" genders.
Clinical Trials Status at Xianmin Song
Currently, there are NaN active trials in "Xianmin Song".
undefined are not yet recruiting,
4 are recruiting,
undefined are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were undefined completed trials in Xianmin Song,
undefined suspended trials,
and undefined terminated clinical trials to date.
Out of the total trials that were conducted in Xianmin Song, 1 "Phase 1"
clinical trials were conducted, 0 "Phase 2" clinical
trials and 0 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 2 trials, and there were
also 1 trials that are defined as “Not Applicable".